期刊文献+

雌激素受体β干扰质粒对前列腺癌PC3细胞生物学行为的影响及ERK1/2信号通路的作用 被引量:2

下载PDF
导出
摘要 目的探讨雌激素受体β(ERβ)干扰质粒对前列腺癌PC3细胞生物学行为的影响,以及ERK1/2信号通路在其中的作用。方法针对ERβ特定靶定位置,构建干扰质粒psilencer-2.1-U6-neo-sh ERβ(sh ERβ),利用Lipofectemine2000作为载体将sh ERβ转染PC3细胞,采用G418筛选稳定低表达ERβ的PC3细胞。Real-time PCR及Western blot检测ERβ的表达。实验分为空白对照组、阴性对照组、sh ERβ组,将3组细胞注射在裸鼠皮下建立移植瘤模型,空白对照组未加入任何处理因素;阴性对照组转染空质粒psilencer-2.1-U6-neo;sh ERβ组转染重组质粒psilencer-2.1-U6-neo-sh ERβ。绘制肿瘤生长曲线和称取瘤重;应用免疫组织化学检测肿瘤组织ERβ的表达及ERK1/2活化;应用Western blot检测肿瘤组织VEGF的表达。结果测序比对分析表明成功完成了干扰质粒psilencer-2.1-U6-neo-sh ERβ的构建,Real-time PCR及Western blot结果显示成功转染并筛选出稳定低表达ERβ的PC3细胞。体内成功建立PC3细胞裸鼠移植瘤模型,移植瘤生长曲线显示sh ERβ组移植瘤生长速度明显快于其他两组。免疫组化结果显示ERβ阳性表达sh ERβ组最低;ERK1/2阳性表达在3组之间无明显差异,p-ERK1/2阳性表达sh ERβ组最高(P<0.05)。Western blot结果显示sh ERβ组VEGF蛋白表达明显高于其他两组(P<0.05)。结论 ERβ可通过抑制ERK1/2信号通路活化来抑制前列腺癌PC3细胞恶性生物学行为。
作者 于洋 索勇
出处 《广东医学》 CAS 北大核心 2017年第18期2768-2772,共5页 Guangdong Medical Journal
  • 相关文献

参考文献6

二级参考文献85

  • 1叶定伟,周芳坚.前列腺癌根治术后复发的诊断和治疗[J].中国癌症杂志,2007,17(3):193-198. 被引量:4
  • 2Singh PB, Matanhelia SS, Martin FL. A potential paradox in prostate adenocarcinoma progression: oestrogen as the initiating driver. Eur J Cancer, 2008, 44: 928-936.
  • 3Cookson MS, Aus G, Burnett AL, et al. Variation in the defini- tion of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical out- comes. J Urol, 2007, 177 : 540-545.
  • 4Ricke WA, McPherson SJ, Bianco JJ, et al. Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J, 2008, 22: 1512- 1520.
  • 5McPherson SJ, Hussain S, Balanathan P, et al. Estrogen recep- tor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNF alpha mediated. Proc Natl Acad Sci U S A, 2010, 107: 3123-3128.
  • 6Nakajima Y, Akaogi K, Suzuki T, et all. Estrogen regulates tumor growth through a nonclassical pathway that includes the transcrip- tion factors ER13 and KLF5. Sci Signal, 2011,4: ra22.
  • 7Bonkhoff H, Berges R. The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol, 2009, 55: 533-542.
  • 8Grubisha M J, Cifuentes ME, Hammes SR, et al. A local parac- rine and endocrine network involving TGFI3, Cox-2, ROS, and estrogen receptor 13 influences reactive stromal cell regulation of prostate cancer cell motility. Mol Endocrinol, 2012, 26: 940- 954.
  • 9Taylor SE, Patel Ⅱ, Singh PB, et al. Elevated oestrogen receptor splice variant ERetA5 expression in tumour-adjaeent hormone- responsive tissue. Int J Environ Res Public Health, 2010, 7: 3871-3889.
  • 10Taylor SE, Martin-Hirsch PL, Martin FL. Oestrogen receptor splice variants in the pathogenesis of disease. Cancer Lett, 2010, 288 : 133-148.

共引文献45

同被引文献12

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部